
Leerink analyst Mike Kratky raised the firm’s price target on AxoGen (AXGN) to $65 from $56 and keeps an Outperform rating on the shares. The firm has growing conviction that
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AXGN | AxoGen | 56.35 | 31.36 | 125.46% |
| Name | Price | % Change | |
|---|---|---|---|
| $56.35 | +125.46% |

Leerink analyst Mike Kratky raised the firm’s price target on AxoGen (AXGN) to $65 from $56 and keeps an Outperform rating on the shares. The firm has growing conviction that

AxoGen (($AXGN)) has held its Q3 earnings call. Read on for the main highlights of the call. AxoGen’s earnings call delivered a strongly positive message, led by rapid revenue growth,

Lake Street raised the firm’s price target on AxoGen (AXGN) to $60 from $58 and keeps a Buy rating on the shares. The firm thinks Prostate can be “a modest

AxoGen ( ($AXGN) ) has provided an update. On November 9, 2026, Axogen posted a corporate presentation outlining its prostate nerve reconstruction opportunity. The presentation described an estimated $754 million

Leerink raised the firm’s price target on AxoGen (AXGN) to $56 from $52 and keeps an Outperform rating on the shares following the company’s Q3 earnings. After yet another strong

Lake Street raised the firm’s price target on AxoGen (AXGN) to $58 from $55 and keeps a Buy rating on the shares after “a solid beat and guide up” in

Mizuho raised the firm’s price target on AxoGen (AXGN) to $65 from $58 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for

Canaccord raised the firm’s price target on AxoGen (AXGN) to $60 from $55 and keeps a Buy rating on the shares. The firm said they posted an impressive Q against

H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $56 from $53 and keeps a Buy rating on the shares following the Q3 report. The company is on

Barclays analyst Christopher Pasquale raised the firm’s price target on AxoGen (AXGN) to $60 from $50 and keeps an Overweight rating on the shares. The company’s “strong” Q3 report shows
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 19, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 28, 2026 | ||||
| buy | Reiterated | Oct 2, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 23, 2027TBA | $3.40B | $0.15 | $83.30M | -2.01 | -87.61 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.